4.7 Article

Deciphering the mutational signature of congenital limb malformations

Journal

MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 24, Issue -, Pages 961-970

Publisher

CELL PRESS
DOI: 10.1016/j.omtn.2021.04.012

Keywords

-

Funding

  1. National Key Research and Development Program of China [2016YFC0901500]
  2. Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China [2016ZX310174-4]
  3. Beijing JST Research Funding [ZR-201907, 2019-YJ03]
  4. Beijing Jishuitan Hospital Nova Program [XKXX20 1818]
  5. National Natural Science Foundation of China [81822030, 82072391, 81672123, 81972037, 81772299, 81930068, 81772301, 81972132]
  6. Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT320025]
  7. Beijing Natural Science Foundation [JQ20032, 7191007]
  8. Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
  9. CAMS Initiative Fund for Medical Sciences [2016-I2M-3-003, 2016-I2M-2-006, 2017-I2M-2-001]
  10. National Students Innovation and Entrepreneurship Training Program [2019-zlgc0609]

Ask authors/readers for more resources

This study aimed to decipher the mutational signature of congenital limb malformations (CLM) using exome sequencing, identifying novel pathogenic variants and candidate genes. By expanding the phenotypic spectrum of CLM, the researchers discovered RPL9 and UBA2 as potential new genes for CLM. The study significantly increased diagnosis rates among patients with a family history of CLM or multiple affected limbs, providing valuable insights into the genetic basis of these syndromes.
Congenital limb malformations (CLMs) affect 1 in 500 live births. However, the value of exome sequencing (ES) for CLM is lacking. The purpose of this study was to decipher the mutational signature of CLM on an exome level. We enrolled a cohort of 66 unrelated probands (including 47 families) with CLM requiring surgical correction. ES was performed for all patients and available parental samples. A definite molecular diagnosis was achieved in 21 out of 66 (32%) patients. We identified 19 pathogenic or likely pathogenic single-nucleotide variants and three copy number variants, of which 11 variants were novel. We identified four variants of uncertain significance. Additionally, we identified RPL9 and UBA2 as novel candidate genes for CLM. By comparing the detailed phenotypic features, we expand the phenotypic spectrum of diastrophic dysplasia and chromosome 6q terminal deletion syndrome. We also found that the diagnostic rate was significantly higher in patients with a family history of CLM (p = 0.012) or more than one limb affected (p = 0.034). Our study expands our understanding of the mutational and phenotypic spectrum of CLM and provides novel insights into the genetic basis of these syndromes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available